"10.1371_journal.pone.0125080","plos one","2015-04-29T00:00:00Z","Karin Neukam; Daniela I Munteanu; Antonio Rivero-Juárez; Thomas Lutz; Jan Fehr; Mattias Mandorfer; Sanjay Bhagani; Luis F López-Cortés; Annette Haberl; Marcel Stoeckle; Manuel Márquez; Stefan Scholten; Ignacio de los Santos-Gil; Stefan Mauss; Antonio Rivero; Antonio Collado; Marcial Delgado; Juergen K Rockstroh; Juan A Pineda","Unit of Infectious Diseases and Microbiology, Valme University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain; RIS-HEP07 Study Group of the Spanish AIDS Research Network; Department of Medicine I, Bonn University Hospital, Bonn-Venusberg, Germany; Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; Unit of Infectious Diseases, Reina Sofía University Hospital, Maimónides Institute of Biomedical Investigation of Cordoba (IMIBIC), Cordoba, Spain; Infektiologikum Frankfurt, Frankfurt/Main, Germany; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna and Vienna HIV & Liver Study Group, Vienna, Austria; Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom; Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain; Department of Medicine II, Frankfurt University Hospital, Frankfurt/Main, Germany; Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Unit of Infectious Diseases, Virgen de la Victoria University Hospital, Malaga, Spain; Praxis Hohenstaufenring, Cologne, Germany; Infectious Diseases Unit, La Princesa University Hospital, Madrid, Spain; Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; Infectious Diseases Unit, Torrecardenas University Hospital, Almeria, Spain; Unit of Infectious Diseases, Carlos Haya Regional University Hospital, Malaga, Spain","Conceived and designed the experiments: KN SB AR AC MD JKR JAP. Performed the experiments: KN DM ARJ TL JF MMan SB LFLC AH MS MMar SS IdlSG SM. Analyzed the data: KN JAP. Contributed reagents/materials/analysis tools: KN JAP. Wrote the paper: KN DM ARJ TL JF MMan SB LFLC AH MS MMar SS IdlSG SM AR AC MD JKR JAP.","J.F. has received research grants and travel grants from Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Roche and ViiV. L.F.L-C. has received unrestricted research funding, consultancy fees, and lecture fees from and has served on the advisory boards of Abbott, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Roche España, and ViiV Healthcare. T.L. reports having received consulting, board membership or advisor fees from Gilead Sciences, AbbVie, Boehringer Ingelheim, Merck Sharp & Dohme and Janssen-Cilag. He has received research grants from Janssen-Cilag, Gilead Sciences, Bristol-Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Merck Sharp & Dohme, Boehringer Ingelheim and Janssen-Cilag, and he has received lecture fees from Bristol-Myers Squibb, Gilead Sciences, Boehringer Ingelheim and Roche. M.Mar. has received lecture fees from Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, and ViiV Healthcare. M.Man. reports having received consulting fees from Janssen-Cilag, lecture fees from Janssen-Cilag and Roche and travel support from MSD and Roche. S.M. has received honoraria for speaking at educational events or consulting from Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Roche, Tibotec, and ViiV Healthcare. K.N. has received lecture fees from Janssen-Cilag, Roche, Bristol-Meyers Squibb and Merck Sharp & Dohme and has received research support from Janssen-Cilag, Bristol-Meyers Squibb, Merck Sharp & Dohme, Gilead Sciences and Abbott Pharmaceuticals. J.A.P. reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim and Schering-Plough. A.R. reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim and Schering-Plough. A.R.J. has received lecture fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, ViiV Healthcare and Roche. J.K.R. has received honoraria for speaking at educational events or consulting from Abbvie, Bionor, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Tibotec, Tobira, and ViiV Healthcare. S.S. reports having received congress sponsoring from Abbott, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, and ViiV Healthcare. He has received lecture fees from Abbott Pharmaceuticals, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Carbonics, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, ViiV Healthcare and Roche, consulting fees from Abbott Pharmaceuticals, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen-Cilag, Pfizer and ViiV Healthcare and study grants from Abbott Pharmaceuticals, Abbvie, Bristol-Myers Squibb, Boehringer Ingelheim, BMG/BMBF, Essex, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, NEAT, Pfizer, University of Bonn, University of Dusseldorf, and ViiV Healthcare. All other authors: none to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","04","Karin Neukam","KN",19,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
